• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Technology Events 2023-2024
  • Sponsored Post
    • Make a Contribution
  • Technology Markets
    • Venture Capital
  • About
  • Contact

Italian Researchers Identify New SARS-CoV-2 Gene Variants That Provide Clues to Coronavirus’s Epidemiology

March 25, 2020 By admin Leave a Comment

Scientists say early data, generated with new NGS research panel from Thermo Fisher Scientific, suggest coronavirus is genetically stable, and could increase the effectiveness of vaccines in development

Two teams of infectious disease researchers in Italy say they have further analyzed the SARS-CoV-2 genome from samples acquired locally to generate early data that reveal a level of genetic variability suggesting the rapidly spreading virus’s genome is stable. The findings, developed using a new next-generation sequencing (NGS) research assay from Thermo Fisher Scientific, increase the likelihood that future coronavirus vaccines can have a higher rate of effectiveness and could help the global scientific community’s effort to better understand the epidemiology and spread of COVID-19.

The two independent research teams from “Lazzaro Spallanzani” National Institute for Infectious Diseases (IRCCS) in Rome and the Forensic Division of the Department of Biomedical Sciences and Public Health (DSBSP) at Ancona University Hospital sequenced multiple samples and identified the presence of gene variants when compared against the original Wuhan coronavirus reference genome. Viruses that mutate rapidly over short periods of time make it challenging to develop effective vaccines that protect people against infection. The low number of variants discovered in the Italian samples two months after the virus was first sequenced in China suggests that SARS-CoV-2, which has infected more than an estimated 64,000 people in Italy and 380,000 globally, is a relatively slow-mutating pathogen. Both teams in Italy carried out the sequencing work with Thermo Fisher’s new Ion AmpliSeq SARS-COV-2 Research Panel, which features a 24-hour, end-to-end workflow.

“The ability to very quickly run multiple samples and accurately decipher key changes in the virus’s genetic code will be crucial for the global scientific community to stay ahead of SARS-CoV-2 and to develop strategies against it that, ultimately, can be leveraged to help resolve the pandemic,” said Dr. Maria Rosaria Capobianchi, head of the Virology Department, Lazzaro Spallanzani National Institute for Infectious Diseases, which was the first research center in Europe to generated whole genome sequencing data of the coronavirus on Thermo Fisher’s Ion Torrent NGS platform. “Viral genomes are dynamic and these preliminary data need further analysis to determine the biological significance of the gene variants and to investigate the evolutionary path of the coronavirus.”

Professor Stefano Menzo, head of Virology at Ancona University Hospital, said: “Had we investigated other viruses we might have expected up to dozens of new mutations after so many infectious cycles in patients. Our initial data show that this is a very stable RNA virus, with only five novel variants. A virus with a stable genome is good news for vaccine development because it indicates that the effectiveness of vaccines could be more consistent, possibly over many years.”

The scientists now plan to further analyze the data with Thermo Fisher’s new Ion SARS-CoV-2 analysis solution* for variant annotation and consensus sequencing assembly to better understand the impact on disease severity, mode of transmission, and phylogenetic studies. The Ion AmpliSeq SARS-COV-2 Research Panel is a targeted NGS solution that analyzes the entire SARS-CoV-2 genome. It provides an efficient, high-throughput end-to-end workflow for monitoring genomic evolution, which is critical during a rapidly developing pandemic. The panel is optimized to run on the Ion GeneStudio S5 Systems.*

Panel Optimization for Genexus System Underway
To further expedite NGS analysis of SARS-CoV-2 and to help meet growing customer demand, Thermo Fisher has begun to optimize the Ion AmpliSeq SARS-COV-2 Research Panel for the Ion Torrent Genexus System.* Launched in November 2019, the company’s newest sequencing platform automates the entire targeted NGS workflow and can deliver specimen to report economically in as little as 14 hours. Optimization and validation of the research panel on the Genexus System is now underway in collaboration with Thermo Fisher customers.

“Thermo Fisher’s immediate response to first develop a PCR SARS-CoV-2 diagnostic** assay and now a next-generation sequencing research solution to help customers investigate coronavirus is at the core of our mission,” said Peter Silvester, senior vice president and president of Life Sciences Solutions at Thermo Fisher Scientific. “We share the global community’s heightened concern during this unprecedented public health crisis and, for this reason, we are continuing to maximize our efforts to provide our laboratory partners, infectious disease researchers and vaccine developers with the most advanced tools in support of their very important work.”

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

* For Research Use Only. Not for use in diagnostic procedures.

** Designation as an IVD or as an IVD for emergency use / special access varies from region to region.

Filed Under: Tech Tagged With: COVID-19, COVID-19 Vaccine, Coronavirus

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

Unfulfilled Dreams: The Aftermath of China’s Stalled Real Estate Developments
Huawei on the Brink: Biden Administration Considers Cutting Off the Tech Giant”
Key Fire Industry Trends for 2023
The Future of Food: Top Trends to Watch in 2023 and Beyond
How to discover the treasure trove of hidden marketing insights by watching customer behavior
Navigating Uncertainty: Prioritizing Hydrogen R&D Efforts for a Sustainable Future
Unleashing the Hidden Talent Pool: The Rise of STARs – Skilled Through Alternative Routes

Market Research Media

Turn Your Story into a Game: The Art of Gamifying Your Plot
The end of cheap money is redrawing the map of corporate earnings
The Future of Virtual Reality: How VR is Changing Industries
Market Research Media Survey: The State of Streaming Services
Media measurement services provide a holistic view of cross-media consumption
Gen Z ranks top in luxury sales
How to market recycled products

Secondary Sidebar

Tech Events

The crypto world is facing a crisis of confidence
ScyllaDB Summit 2023 taking place online on February 15-16, 2023
DLD 2023, an innovation festival, February 1-3, 2023, Tel Aviv, Israel
Cybersecurity Innovations Take Center Stage at Cybertech 2023 in Tel Aviv
Chiplet Summit, January 24-26 2023, the Doubletree by Hilton San Jose Hotel

Venture Capital

The Importance of Diversity and Inclusion in the Workplace
Sequoia Capital announces its $195 Mln dedicated seed fund
Sublime Systems Secures $40 Million Series A to Electrify and Scale Decarbonized Cement Production
actyv.ai Raises Pre-Series A Funding to Fuel Global Expansion, Product Enhancement
Ottopia announces $14.5M Series A Funding Round

Footer

Recent Posts

  • Netlify has acquired Gatsby
  • Potential for disruption: Conference is the most inefficient way to get information
  • Artificial Intelligence: The Future of Healthcare
  • The Rise of Virtual Power Plants: Innovating Energy Management
  • DLD 2023 is coming
  • Barcelona Cybersecurity Congress Has Been a Success
  • The Unstoppable Rise of RISC V Architecture
  • Revolutionizing Education: The Power of Automated Tutoring Lessons
  • Revolutionizing the Fashion Industry: Algae-based Yarns and Dyes Take on Fast Fashion
  • Cybertech 2023 kicks off in Tel Aviv

App Coding

Code Intelligence raises $12M Series A
Digital twins transform the efficiency of current business processes
Ondat 2.8 Arrives in GA with Increased Support for Stateful Workloads in Kubernetes
Jotform Store Builder launches as a no-code solution to build a store in minutes
monday.com Adds Built-In Monetization Solution to the apps marketplace

API Coding

API-based startup that connects African businesses
Creating an API that generates a description of an image using ChatGPT
Most commonly used HTTP Headers
Apple Provides Developers with Even More Powerful Technologies to Push the App Experience Forward
How to teach yourself API coding

Blockchaining

New York just passed a bitcoin mining ban
How safe are NFTs as digital assets
The Fascinating World of Cryptocurrency
State of Technology Overview: Blockchaining 2023
How safe is blockchain technology behind cryptocurrencies

Event Calendar

NAHB International Builders’ Show (IBS 2023) in Las Vegas from January 31 to February 2, 2023
India’s largest biennial automobile exhibition Auto Expo 2023 held on January 12-15, 2023 at Pragati Maidan, New Delhi
NRF 2023, Retail’s Big Show and Expo, January 15 to 17, 2023, Jacob K. Javits Center, New York
DOMOTEX Hannover 2023′ in Germany from 12-15 January
Electrify Expo Austin Set to Be Largest EV Demo Event of the 2022 Season, November 12-13, 2022, Austin, Texas

Copyright © 2022 Technologies.org

Media Partners: Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT